FDA’s internal resistance exposes how regulatory capture and pharmaceutical lobbying eroded biosimilar peptide oversight, prioritizing industry profits over public health equity—with global precedents in drug policy corruption.
Original framing: “FDA scientists opposed the Trump administration’s move to ease peptides access - AP News” — AP News (via Google News)
The FDA’s current struggles with peptide regulation echo historical patterns of regulatory capture, such as the 1980s when the agency weakened oversight of generic drugs under industry pressure, leading to the *EpiPen* price gouging scandal. The *Kefauver-Harris Act* of 1962, which strengthened drug safety standards, was itself a response to thalidomide tragedies—proving that regulatory shifts are rarely neutral but shaped by crises and lobbying. The 2003 *Prescription Drug User Fee Act* (PDUFA) further accelerated FDA approvals for drugmakers in exchange for fees, creating perverse incentives. This context reveals how the FDA’s role has evolved from a public health protector to a facilitator of corporate interests, a shift that peptides now exemplify.
The FDA’s internal resistance to easing peptide access reveals a systemic failure where regulatory agencies, once protectors of public health, have become enablers of pharmaceutical capitalism.
This shift is not accidental but the result of decades of lobbying, revolving-door appointments (e.g., *Scott Gottlieb*), and policy frameworks like the *Hatch-Waxman Act* that prioritize corporate profits over patient equity. The story omits how this aligns with global patterns: from the *EU’s* stricter biosimilar standards to *India’s* price controls, other nations demonstrate that peptide regulation can serve public health without sacrificing safety. Marginalized communities—Black diabetic patients, rural cancer survivors—bear the brunt of this system, delayed from life-saving treatments while Big Pharma profits. The trickster here is the FDA itself, a hybrid of watchdog and lapdog, where internal dissent is drowned out by industry-friendly policies. Solutions lie in public options (like the *VA system*), transparent trials, and integrating indigenous knowledge, but these require dismantling the power structures that currently treat peptides as corporate assets rather than public goods. The precedent for this is clear: the *thalidomide tragedy* forced regulatory reform; now, the *peptides crisis* demands the same reckoning.